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Background: Prior reports suggest a link between gonadotropin-releasing hormone (GnRH) and gastrointestinal
function. The aim of the study was to prospectively investigate women subjected to in vitro fertilization (IVF) using
the GnRH analog buserelin, taking into account gastrointestinal symptoms and antibody development against
buserelin, GnRH, luteinizing hormone (LH), and their receptors.
Methods: Gastrointestinal symptoms were registered by the Visual Analogue Scale for Irritable Bowel Syndrome
(VAS-IBS) before and after IVF treatment, and five years later. Health-related quality of life was evaluated by the
36-item Short-Form questionnaire (SF-36). ELISA was used for antibody analyses before and after treatment. Data
were compared with women from the general population.
Results: In total, 124 patients were investigated before and after IVF, and 62 were re-evaluated after five years.
Buserelin treatment led to significant impairment of constipation (p = 0.004), nausea and vomiting (p = 0.035),
psychological well-being (p = 0.000), and the intestinal symptoms’ influence on daily life (p = 0.027). At 5-year
follow-up, abdominal pain was worsened (p = 0.041), but psychological well-being was improved (p = 0.036),
compared to prior treatment, and 15% had an observable deterioration in gastrointestinal symptoms. None
developed severe dysmotility. Patients had higher prevalence of IgG antibodies against LH (p = 0.001) and its
receptor (p = 0.016), and IgM antibodies against the GnRH receptor (p = 0.001) prior treatment compared with
controls, but no antibody development was observed after IVF.
Conclusion: Patients experience gastrointestinal symptoms during buserelin treatment, and abdominal pain is
still increased after five years, but buserelin does not increase antibody formation against GnRH, LH or their
receptors.
Keywords: Abdominal pain, Gastrointestinal symptoms, Gonadotropin-releasing hormone, In vitro fertilization,
Luteinizing hormoneBackground
Irritable bowel syndrome (IBS) affects approximately
10%–15% of the western population, women 1.5–3
times more often than men [1]. To explain why women
are affected to a larger extent than men, connections
between sex hormones, particularly progesterone, and
gastrointestinal function have been proposed [2,3].
Gonadotropin-releasing hormone (GnRH) is the hypo-
thalamic hormone in the sex hormone axis, which stim-
ulates release of follicle-stimulating hormone (FSH) and* Correspondence: bodil.ohlsson@med.lu.se
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reproduction in any medium, provided the orluteinizing hormone (LH), and subsequently estrogen
and progesterone [4].
The role of GnRH in gastrointestinal function has
only been rudimentarily examined. Huang W et al. [5]
have shown GnRH- and GnRH receptor (GnRH-R) im-
munoreactivity in the epithelium and myenteric ganglia
of small and large rat intestine, and the GnRH analog
leuprolide acetate has by unknown mechanisms been
shown to stimulate cycling motor activity in rat gut [6].
Gonadotropin-releasing hormone is also present in the
human enteric nervous system (ENS) [7], and anti-
bodies against the peptide are more common in IBS-
and dysmotility patients as compared with controls [8].
Continuous treatment with leuprolide significantlyal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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orexia, and abdominal distension in patients with func-
tional bowel disease [9,10]. On the contrary, chronic
intestinal pseudo-obstruction (CIPO) was developed
after repeated treatment with the GnRH analog busere-
lin in the setting of in vitro fertilization (IVF). Full-
thickness biopsy showed enteric neurodegeneration
with almost total absence of GnRH-containing neurons
[11]. Scrutiny of 22 patients who had undergone full-
thickness biopsy due to severe, gastrointestinal motility
disorders, i.e. CIPO or enteric dysmotility (ED), re-
vealed five patients with lowered levels of enteric
GnRH-containing neurons and elevated levels of serum
antibodies against GnRH. Three of these five had had
repeated treatments with GnRH analogs in an IVF set-
ting and/or due to endometriosis [7]. Repeated busere-
lin treatment of rats led to 50% loss of enteric neurons
[12].
As IVF is given repeatedly to young women, the same
population which is most likely to be affected by gastro-
intestinal symptoms and dysmotility [1], and sporadic
cases of severe dysmotility have been reported after IVF
[7,11], we found it important to examine possible con-
nections between IVF and IBS or dysmotility in an IVF
cohort. The aim of the present study was thus to pro-
spectively investigate women subjected to IVF using
buserelin treatment, taking into account gastrointestinal
symptoms in relation to treatment as well as five years
later. The presence of antibodies against buserelin,
GnRH, LH, and their receptors, before and after treat-
ment, were also evaluated.Methods
This study was approved by the Ethics Review Board of
Lund University and performed in accordance with the
declaration of Helsinki. All subjects gave their written,
informed consent before inclusion in the study. Naïve
blood samples from the patients taken during the very
first pre-IVF screening was used in accordance with the
Swedish Act ’Biobanks in Medical Care Act‘ (SFS
2002:297).Patients
Patients were recruited to the study at a fertility clinic in
Malmö where they sought care for infertility. The clinic
receives patients from the southernmost districts of
Sweden. The reasons for the infertility were not further
investigated. After appropriate consultation, an IVF re-
gime was planned. One selected nurse was responsible
for recruiting consecutive patients passing her with a
planned regime involving the GnRH analog buserelin,
from 2007 through 2008.Controls
Two age- and gender-matched controls for each included
patient were randomly acquired from the Swedish Popula-
tion Registry at the 5-year follow-up. Thus, 248 women
were contacted via mail. After one reminder, 29 question-
naires were returned. As the response rate was low, fur-
ther controls were recruited amongst hospital staff. In
total, 65 healthy women, median age 37 (IQR 34–42)
years, were recruited and completed the questionnaires.
Blood samples from 169 consecutive healthy female
blood donors, median age 45 (IQR 31–54) years, col-
lected at Skåne University Hospital, Malmö, served as a
control group for antibody analyses within the study.
Study design
Figure 1 illustrates the study design. Patients underwent
IVF according to clinical routines. The Visual Analogue
Scale for Irritable Bowel Syndrome (VAS-IBS) was com-
pleted and the IVF treatment started with two nasal in-
halations of the GnRH analog buserelin (Suprecur®,
Sanofi-Aventis, Bromma, Sweden) four times a day for
three weeks; dose was varying according to clinical re-
sponse. The VAS-IBS was again completed after these
three weeks and blood samples collected. Blood samples
consisted of 7.0 ml whole blood drawn into heparinized
or untreated tubes. Plasma and serum were separated
and immediately frozen at −20°C. This was followed by
one inhalation four times a day for another two weeks,
along with FSH and human chorionic gonadotropin
(hCG) administered according to clinical routines. The
total dose of buserelin was 28.8 (IQR 27.0–31.6) mg.
Treatment naïve blood samples were obtained from the
Department of Medical Microbiology, Skåne University
Hospital, Malmö. Sera were analyzed for the presence of
antibodies against buserelin, GnRH, LH, and their
receptors.
Five years after the initial treatment, the VAS-IBS
questionnaire and the 36-item Short-Form questionnaire
(SF-36) were sent to patients and matched controls. One
reminder was sent within one month, if no reply was
returned.
Questionnaires
Visual Analogue Scale for Irritable Bowel Syndrome
The VAS-IBS was used to estimate gastrointestinal com-
plaints. This is a validated questionnaire for estimation
of the most common gastrointestinal complaints in pa-
tients with functional, non-organic bowel disease [13].
This instrument has also been validated for evaluation of
symptoms over time [14]. The seven VAS items used
assess each of the following symptoms: abdominal pain,
diarrhea, constipation, bloating, nausea and vomiting,
psychological well-being, and intestinal symptoms’ influ-
ence on daily life. The scale measures from 0–100 mm,
Patients – 
Inclusion at fertility clinic
(124)
Controls – healthy female blood  
donors (169)





VAS-IBS and blood samples




Recruitment of blood samples
from biobank, prior to first IVF
(96)
VAS-IBS and SF-36
Antibody analyses Antibody analyses 
Antibody analyses 
Figure 1 Flow chart over the study design. VAS-IBS = Visual Analogue Scale for Irritable Bowel Syndrome. FSH = Follicle-stimulating hormone,
hCG = human chorionic gonadotropin, IVF = In vitro fertilization.
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sent absence of problems. Two questions at the end of
the form are to be answered with yes or no; feeling of
incomplete evacuation and presence of tenesms.
36-item Short-Form questionnaire
The SF-36 was used to assess health-related quality of life
(HRQOL). It is a generic questionnaire divided into eight
subscales of general health and ordered according to which
degree they measure physical or mental health. Four sub-
scales correspond mainly to the Physical Composite Score
(PCS), namely, physical functioning (PF), role physical
(RP), bodily pain (BP), and general health (GH). Four sub-
scales correspond mainly to the Mental Composite Score
(MCS), namely, vitality (VT), social functioning (SF), role
emotional (RE), and mental health (MH). The subscales
GH, VT, and SF also correspond with the PCS [15]. SF-36
is an extensively used HRQOL instrument, which provides
reproducible, reliable data in large populations and is used
as a global health monitor [16]. The maximum score is
100, the higher score the better the HRQOL. Norm-based
scores for the SF-36 questionnaire were calculated for pa-
tients as well as for controls, using the QualityMetric
Health Outcomes™ Scoring Software 4.5 [17].
Measurement of antibodies against buserelin, GnRH and
GnRH receptor
Analyses of antibodies against GnRH and GnRH-R were
carried out by an ELISA as described previously [18]. The
wells of microtiter plates (456537 Nunc, Roskilde,
Denmark) were either coated with buserelin (Suprefact®
lot 2 F0174, Sanofi-Aventis, Bromma, Stockholm), or hu-
man GnRH or N-terminal GnRH-R peptide ((NH2)-ANSASPEQNQNHCSAINNSIPLMQGNLPY) conjugated
with ovalbumin (OVA) (Innovagen, Lund, Sweden), in an
overnight incubation at 4°C. Thereafter the plastic wells
were blocked with 0.5% bovine serum albumin (BSA) (A-
7030, Sigma, St Louis, USA) in phosphate-buffered saline
(PBS) containing 0.05% Tween-20 (PBS-T). The dilutions
of patient serum (1:400 in 1.0 μg OVA (A-5503, Sigma)/
ml 0.5% BSA in PBS-T) or mouse anti-human GnRH anti-
body (ab62432, Abcam, Cambridge, MA, USA) in serial
dilution (to construct a standard curve) were then added
to the plates and incubated for 2 h at room temperature
(RT). After rinsing with PBS-T, deposition of antibodies
directed to buserelin, GnRH or GnRH-R was detected
using biotinylated rabbit anti-human IgM- (673211, MP
Biomedicals, Solon, OH, USA), IgG- (ab7159, Abcam), or
IgA antibodies (ab97218, Abcam), or goat anti-mouse IgG
antibodies (E0433, DAKO, Glostrup, Denmark) appropri-
ately diluted in PBS-T. After another incubation for 2 h at
RT, the plates were washed and the bound, biotinylated
antibodies detected by alkaline phosphatase-conjugated
streptavidin (405211, Biolegend, San Diego, CA, USA), in-
cubated for 1 h at RT. To develop a color reaction, a phos-
phatase substrate kit (37620, Pierce, Rockford, Ill, USA)
was used. The absorbance at 405 nm was measured after
30 min of incubation at RT. Antibody levels are expressed
as relative units (RU) (absorbance values after subtracted
background levels and multiplied with 1000). The cut-off
value to determine presence of antibodies in the control
group of 169 healthy female blood donors was defined as
RU >97.5th percentile. The intra-assay correlation coeffi-
cient of variation (CV) of GnRH- and GnRH-R IgM
antibodies was 10% and 8%, respectively (n = 6), and inter-
assay CV was 11% and 6%, respectively (n = 12). No
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bodies or buserelin antibodies was calculated due to lack
of positive serum.
For competitive ELISA, diluted sera from patients with
antibodies above the cut-off level were incubated in
0.05% BSA in PBS-T with various amounts of GnRH or
GnRH-R peptide, both unconjugated and conjugated
with OVA (Innovagen), prior to application to the mi-
crotiter plate.
Measurement of antibodies against LH and LH receptor
An in-house ELISA was set up for analysis of anti-IgG-
and anti-IgM antibodies against LH and its receptor
(LH-R).
LH
The microtiter plates (456537, Nunc) were coated with
intact, purified, native human LH (MBS537383, MyBio-
source, San Diego, CA, USA) in PBS-T or only PBS-T
(to provide an internal blank). After overnight incuba-
tion at 4°C, the plates were washed three times with
PBS-T and blocked with 0.5% BSA in PBS-T. Dilutions
of serum (1:200) from patients and blood donors, or
rabbit anti-human LH antibody (MBS535386, MyBio-
source) in serial dilution (to construct a standard curve),
with BSA in PBS-T were then added to the plates in
triplicate (two wells coated with LH and one well coated
with PBS-T) and incubated for 2 h at RT. The washing
procedure was repeated and deposition of autoantibodies
directed to LH was detected using biotinylated rabbit
anti-human IgM- (673211, MP Biomedicals) or IgG anti-
bodies (ab7159, ABcam), or goat anti-rabbit IgG anti-
bodies (B7389, Sigma) appropriately diluted in PBS-T.
LH receptor
Microtiter plates were coated with the N-terminal LH-R
peptide ((NH2)-MKQRFSSALQLLKLLLLQPPLPRALC),
conjugated with OVA (Innovagen), in 100 mM Carbon-
ate buffer pH 9.2 or only Carbonate buffer (to provide
an internal blank). After overnight incubation at 4°C, the
plates were washed three times with PBS-T and blocked
with 0.5% BSA in PBS-T. Dilutions of serum (1:200)
from patients and blood donors with BSA in PBS-T were
then added to the plates in triplicate, two to LH-R and
one to Carbonate buffer-coated wells, and incubated for
2 h at RT. The washing procedure was repeated and
deposition of autoantibodies directed to LH-R was
detected using biotinylated rabbit anti-human IgM-
(673211, MP Biomedicals) or IgG antibodies (ab7159,
Abcam) appropriately diluted in PBS-T.
To develop a color reaction, a phosphatase substrate kit
(37620, Pierce) was used. The absorbance at 405 nm was
measured after 30 min (LH IgM and LH-R) or 60 min
(LH IgG) of incubation at RT. Antibody levels arepresented as RU (absorbance values after subtracted back-
ground levels and multiplied with 1000) and the cut-off
value to determine presence of antibodies in the control
group of 169 healthy female blood donors was defined as
RU >97.5th percentile. The intra-assay CV of LH IgG and
LH IgM was 5.6% and 9.2%, respectively (n = 8), and inter-
assay CV of LH IgG and LH IgM was 7.7% and 6.1%,
respectively (n = 17). No intra-assay or inter-assay CV of
LH-R was calculated due to lack of appropriate commer-
cial antibody.
For competitive ELISA, diluted sera from patients
with antibodies above the cut-off level were incubated
in 0.5% BSA in PBS-T with various amounts of LH
(MBS537383, MyBiosource) or LH-R, unconjugated
and conjugated with OVA (Innovagen), i.e. 50, 100, or
200 ng/100 μl, 30 min prior to application to the
microtiter plates.
Statistical methods
The data were analyzed using the statistical software
package SPSS for Windows© (Release 20.0; IBM). All
variables were analyzed for normal distribution by
Kolmogorov-Smirnov test. As normality was rejected,
the Wilcoxon’s signed rank test was used to calculate
differences within the group and the Mann-Whitney
U-test to compare different groups. When appropriate,
Fisher’s exact test was used. Spearman’s rank correlation
test was applied for correlations. Values are expressed as




The median age of the 124 included patients was
34 years, IQR 31–37 years, at the time of IVF treatment.
All except one completed the VAS-IBS questionnaire.
Twelve percent were current smokers. An anamnesis of
past or concurrent diseases was present in 51 patients
(49%). The most common diseases were endometriosis
(15 (12%)), asthma (8 (6%)), and hypothyroidism (8
(6%)) (Additional file 1: Table S1). Thirty-two percent of
the patients reported some kind of allergy. Only one of
the patients was currently unemployed. Forty percent of
the women were subjected to IVF treatment for the first
time, 24% had IVF treatment for the second time, 23%
for the third time, and 14% had had four or more treat-
ments when investigated. At most, one patient had had
eight prior IVF treatments.
Gastrointestinal symptoms before and after buserelin
treatment
The patients had more nausea and vomiting already
before treatment compared with controls (95 (87–98)
and 98 (92–99), respectively, p = 0.011).
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buserelin had significant negative effects on constipation,
nausea and vomiting, psychological well-being, and the
intestinal symptoms’ influence on daily life (Table 1).
The increased abdominal pain and bloating after treat-
ment showed a tendency towards significance, p = 0.052
and p = 0.079, respectively, whereas diarrhea was not
significantly influenced by the treatment (Table 1). No
correlation was found between age and VAS-IBS param-
eters (data not shown). No differences were detected
regarding feeling of incomplete evacuation and need to
defecate (data not shown).5-year follow-up of gastrointestinal symptoms and
health-related quality of life
Sixty-two of the initial 124 included women (49%)
returned their questionnaires at follow-up after one re-
minder. There was no difference in base-line characteris-
tics or VAS-IBS scores between those who returned
their questionnaires after five years or not (data not
shown). Abdominal pain had been worsened at the 5-
year follow-up, but psychological well-being had been
improved as compared with the measurements before
treatment (Table 1). Nine of 62 patients (15%) had
prominent negative deviations in VAS-IBS compared
with before treatment. These were contacted by tele-
phone, and the aggravation in symptoms seemed to be
explained by development or exacerbations of IBS symp-
toms. Three of these had become pregnant and got chil-
dren after IVF, and two of them had an anamnesis of
endometriosis. None had developed severe dysmotility.
Two patients had prominent positive deviations in VAS-
IBS at follow-up. There was no difference in VAS-IBS
between controls and patients at 5-year follow-up (data
not shown). There was no difference in abdominal pain
between those patients with an anamnesis of endometri-





median (IQR) median (IQR)
Abdominal pain 92 (79–97) 86 (68–96)
Diarrhea 94 (82–97) 93 (80–96)
Constipation 93 (79–97) 86 (67–96)
Bloating 77 (61–94) 74 (50–88)
Nausea and vomiting 95 (87–98) 95 (84–97)
Psychological well-being 87 (69–96) 78 (52–93)
Intestinal symptoms’ influence on daily life 93 (77–98) 90 (77–96)
A lower value of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) i
(IQR). Wilcoxon’s signed rank test or Mann-Whitney U-test were used. P < 0.05 was cquestionnaire (p = 0.341, p = 0.312, and p = 0.114,
respectively).
Norm-based scores from SF-36 were above norm
values for all domains in controls and patients five years
after treatment, using normative data from the Quality-
Metric 2009 general population sample (Figure 2). The
only significant difference across groups was in the sub-
scale role emotional, where patients scored norm-based
median 56.2 (55.3–56.2) compared to 56.2 (49.2–56.2) in
controls (p = 0.012). No correlations could be found
between the number of IVF treatments and any of the
VAS-IBS- or SF-36 variables (data not shown).
Antibody measurements
All antibodies measured were found in low prevalence
in controls, without any age-related differences in preva-
lence. At most, 1–3 subjects in every 10-year period
expressed antibodies. Sera were available both before
and after IVF treatment in 96 of the 124 patients (77%).
IgA- and IgG antibodies against GnRH and GnRH-R
were uncommon in both patients and blood donors, and
were not further analyzed since none or maximum two
individuals were regarded as positive in each group. No
antibodies against buserelin were detected. Regarding
IgM antibodies against GnRH and GnRH-R, patients
expressed GnRH-R IgM antibodies to a higher extent
before treatment as compared with controls (Table 2).
Competitive ELISA showed that the antibody-binding
capacity to the solid phase was reduced with 25%–63%,
dependent on the amount of antigen added (1.0–5.0 ng/
ml) to the diluted serum before application on the mi-
crotiter plate. There was no difference before or after
buserelin treatment in GnRH- and GnRH-R antibody
prevalence or level (Tables 2 and 3). Two patients had a
prominent increase (about 100 fold) in GnRH-R
antibody concentrations during IVF treatment. One
of these had pronounced symptoms in VAS-IBS parame-





Before vs. Before vs. Before vs.
median (IQR) median (IQR) After Follow-up Controls
84 (71–97) 93 (73–98) 0.052 0.041 0.881
95 (78–98) 95 (80–98) 0.617 0.778 0.812
93 (73–97) 95 (83–98) 0.004 0.839 0.107
73 (59–95) 80 (39–95) 0.079 0.850 0.861
97 (93–99) 98 (92–99) 0.035 0.305 0.011
93 (79–98) 85 (74–96) 0.000 0.036 0.682
94 (70–98) 96 (75–98) 0.027 0.928 0.703
ndicates worse symptoms. Values are given as median, interquartile range
onsidered statistically significant.
Figure 2 Self-reported health-related quality of life using the Short Form 36 (SF-36) questionnaire in 65 controls and 62 patients. Four
subscales correspond mainly to the Physical Composite Score (PCS): PF = Physical functioning, RP = Role physical, BP = Bodily pain and GH =
General health. Four subscales correspond mainly to the Mental Composite Score (MCS): VT = Vitality, SF = Social functioning, RE = Role emotional,
MH =Mental health. Subscales GH, VT, and SF also correspond with the PCS. Median values of norm-based scores for the different groups are pre-
sented. The Quality metric software employs a linear T-score transformation with mean = 50 and standard deviation = 10, utilizing normative data
from the QualityMetric 2009 General Population Sample [17].
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had not been subjected to subsequent GnRH treatments.
The other patient had few symptoms in VAS-IBS both
before and during treatment, but was unfortunately lost
to follow-up. Patients with antibodies against GnRH-R
before treatment had more abdominal pain compared to
controls at baseline (81 (56–93) and 93 (77–97), respect-
ively, p = 0.047) and more influence by gastrointestinal
symptoms on daily life (83 (40–94) and 94 (79–98), re-
spectively, p = 0.020).
The prevalence of LH- and LH-R IgG antibodies was
significantly higher in patients before IVF treatment
compared to controls, with a tendency to higherTable 2 The prevalence of antibodies against gonadotropin-r
their receptors
Patients before IVF Patients after IVF
N = 96 N = 96
GnRH IgM, n (%) 5 (5.2) 3 (3.1)
GnRH-R IgM, n (%) 13 (13.5) 10 (10.4)
LH IgM, n (%) 5 (5.3) 2 (2.1)
LH IgG, n (%) 14 (14.6) 5 (5.3)
LH-R IgM, n (%) 6 (6.3) 6 (6.3)
LH-R IgG, n (%) 9 (9.4) 9 (9.4)
BD = Blood donors, IVF = in vitro fertilization, n (%) = number of patients. Antibody l
healthy female blood donors were considered as presence of antibodies. No IgG an
(2-sided). P < 0.05 was considered statistically significant.prevalence also compared to patients after treatment
(Table 2). The antibody titers are shown in Table 3.
Competitive ELISA regarding LH showed that the
antibody-binding capacity to the solid phase was re-
duced with 43%–87%, dependent on the amount of anti-
gen added (1.0–5.0 ng/ml) to the diluted serum before
application on the microtiter plate.
Discussion
Prospective evaluation of 124 patients who underwent
IVF treatment showed that buserelin led to several
gastrointestinal symptoms when administered. At 5-year
follow-up, none of the 62 re-investigated patients (49%)eleasing hormone (GnRH), luteinizing hormone (LH), and
Blood donors BD vs. before IVF Before vs. after IVF
N = 169 P-value P-value
4 (2.4) 0.292 0.721
4 (2.4) 0.001 0.657
5 (3.0) 0.504 0.444
5 (3.0) 0.001 0.051
6 (3.6) 0.362 1.000
4 (2.4) 0.016 1.000
evels above the cut-off of relative units >97.5th percentile in a cohort of 169
tibodies against GnRH or its receptor were found in patients. Fisher’s exact test
Table 3 The titer of antibody levels against gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and
their receptors
Patients before IVF Patients after IVF Blood donors BD vs. before IVF Before vs. after IVF
RU RU RU P-value P-value
GnRH IgM (≥85) 113 (102–136) 113 (89-) 159 (116–196) 0.190 0.607
GnRH-R IgM (≥75) 103 (88–256) 179 (102–350) 116 (86–134) 0.785 0.343
LH IgM (≥0.82) 0.9 (0.9-1.6) 1.1 (0.8-) 0.9 (0.8-2.2) 1.000 0.857
LH IgG (≥2.0) 3.0 (2.3-4.6) 4.3 (2.4-9.2) 2.7 (2.1-7.6) 0.839 0.511
LH-R IgM (≥166) 240 (194–504) 214 (185–649) 232 (158–310) 0.699 0.732
LH-R IgG (≥338) 452 (379–582) 406 (366–609) 559 (447–742) 0.330 0.863
BD = Blood donor, IVF = in vitro fertilization. Antibody levels are expressed as relative units (RU). The cut-off of RU >97.5th percentile in a cohort of 169 healthy
female blood donors were considered as presence of antibodies, and level was calculated only in positive samples. No IgG antibodies against GnRH or its receptor
were found in patients. Values are given as median, interquartile range. Wilcoxon’s signed rank test or Mann-Whitney U-test were used. P < 0.05 was considered
statistically significant.
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The group had increased abdominal pain compared with
prior treatment, and nine of the 62 women (15%) had
pronounced symptoms that were interpreted as exacer-
bation or development of IBS. On the other hand,
the psychological well-being had improved. Patients had
higher prevalence of IgM GnRH-R antibodies and IgG
LH and LH-R antibodies compared to controls, but
without detectable antibody development during treatment.
Treatment with buserelin is associated with gastro-
intestinal side effects [19], and IVF is associated with
many psychological aspects that also might affect gastro-
intestinal function [20]. The absence of antibody forma-
tion during treatment suggests that the previous
described antibody occurrence in women with GnRH-
induced dysmotility was secondary to the disease, and
not due to the treatment per se [7,11]. Additional factors
such as a previous susceptibility, genetic factors or con-
current infection might have been involved in these
cases, explaining their GnRH-related severe dysmotility
[7]. The fact that buserelin can lead to constipation and
nausea and vomiting during treatment, underlines prior
speculations regarding the role of GnRH on the ENS
and gastrointestinal motor control [4,21]. The symptoms
most prominent in this study during GnRH treatment
are the same symptoms which have been most promin-
ent in the patients with persistent dysmotility after IVF
[7,11]. The persistent increase of abdominal pain may
reflect a permanent damage to the ENS, in line with the
enteric neurodegeneration evoked in a rat model [12]. In
vitro fertilization renders a great psychological stress,
and impaired psychological well-being just prior to treat-
ment is not surprising [20]. After five years, infertile
couples may either have got children or accepted the in-
fertility, explaining the improved well-being at follow-
up.
The specific role of GnRH in the gut is not completely
elucidated, but GnRH analogs have been shown to in-
hibit gastric secretion and gastrin release in rat and dog[22,23], to inhibit cell proliferation in gastric epithelium
[24], and to protect enteric rat neurons in culture when
continuously stimulated [25], whereas shorter stimula-
tion inhibits cell proliferation in gastric smooth muscle
cells [26]. Furthermore, GnRH induces apoptosis and
inhibited cell proliferation in several cancer cells [27,28]
and induced enteric neurodegeneration in rat [12]. Two
main explanations to the gastrointestinal effects evoked
could be speculated on. First, endogenous GnRH is se-
creted into the hypothalamic portal circulation in a pul-
satile fashion. It is rapidly degraded and barely
detectable in peripheral circulation. In contrast, system-
ically administered GnRH analogs have longer half-life
and cause greater exposure of the peripheral tissues
[4,29]. GnRH and its receptors have been reported to be
present and influence the rat digestive tract
[5,23,24,26,30], and GnRH analogs have been suggested
to act directly on enteric neurons through a complex
combination of pathways and factors [21,29].
Second, or maybe concurrently, GnRH might act
through the sex hormone axis as it initially raises circu-
lating levels of FSH and LH [4]. Prolonged administra-
tion turns off the release of FSH and LH, the effect
sought in the IVF setting [4]. It is possible that GnRH
exerts its effect on the gastrointestinal tract indirectly;
through pituitary LH release or absence. Luteinizing
hormone has been shown to influence motor activity in
rat small intestine [31]. Furthermore, LH-R were re-
cently described on human enteric neurons [32], and the
expression was decreased after repeated buserelin treat-
ment in rats [12]. The positive effects of continuous
treatment with GnRH analogs to patients with IBS may
be due to the down-regulation of gonadotropins and
gonadal sex hormones [9,10], as these hormones have
negative effects on the gastrointestinal motility [31,33].
This is to our knowledge the first time as antibodies
against LH-R have been analyzed in human serum. The
patients expressed LH- and LH-R IgG antibodies and
GnRH-R IgM antibodies to a greater extent than
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mon and affects over 10% of reproductive women [34].
Diagnostic categories of reasons for female infertility
may involve endometriosis, tubal factors, uterine factors,
ovarian factors, unexplained infertility, and multiple
other causes [34,35]. Autoantibodies directed towards
FSH, LH, and ovarial factors have been described in in-
fertile women and could be indicative of an autoimmune
disorder targeting for instance the ovary [35-37]. Thus,
the current findings of increased autoantibodies already
before treatment could be related to the infertility per se
and reflect an increased autoimmune activity. The de-
creased prevalence of autoantibodies immediately after
buserelin treatment may reflect a down-regulation of the
immune system and IgG levels, described previously
[38]. The association between gastrointestinal symptoms
and antibody expression found in the present study has
to be further studied in the future. However, the expres-
sion of LH-R in both genital organs and gastrointestinal
tract [12,29,32], down-regulation of LH-R after buserelin
treatment [12], and occurrence of serum antibodies
against LH and LH-R, suggest that LH and its receptor
may be one plausible explanation to the connection
between gut and genital organs observed in women
[2,3,7,21]. Antibodies against FSH or its receptor were
not analyzed as these peptides have not been detected in
the digestive tract [39].
The current study has several limitations, where the
most apparent is the loss of patients to follow-up, with a
response rate of 49% after one reminder. Patients who
have experienced side effects of the treatment could theor-
etically be more prone to return the questionnaire. On the
contrary, the patients who have got children after IVF are
maybe not prone to report aggravated symptoms after the
treatment. It would also have been preferable to have
recruited the control group at the time of inclusion of
patients and to have a 5-year follow-up also in the control
group, since it is known that gastrointestinal symptoms in
a Swedish population are varying over time [40]. However,
in both the case of antibodies and symptoms, patients
provide their own controls and the population-based ma-
terial are merely intended to provide a benchmark control
group, since IVF patients could represent a selected group.
At inclusion, patients had more nausea and vomiting
compared with controls. This may depend on that 60% of
patients already had undergone IVF, and thus GnRH treat-
ment, prior to this study, or to the many psychological
factors associated with IVF [20]. Also, some of the 15
patients with past or concurrent endometriosis could have
received GnRH analogs as treatment of their endometri-
osis, although GnRH analogs are not the first choice of
treatment in this entity. To include patients for symptom
registration, and not only blood samples, prior to the first
treatment had been the most optimal.Conclusions
We can conclude that although many patients experi-
ence gastrointestinal side effects during treatment with
the GnRH analog buserelin, and an increase in abdom-
inal pain and improved psychological well-being persists
after five years, no severe dysmotility cases were pro-
spectively observed amongst 62 patients in a 5-year per-
spective. Neither was there any detected development of
antibodies against buserelin, GnRH, LH or their recep-
tors related to buserelin treatment. The results are in
line with prior large epidemiological studies stating that
IVF treatment seems reasonably safe [41]. However, it
remains to identify which patients who are at risk to de-
velop serious, persistent gastrointestinal side effects after
GnRH treatment [7,11].
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